EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION

The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous trastuzumab usage in  Russian population showed  the...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: E. V. Lubennikova, I. P. Ganshina, A. N. Lud, D. V. Komov, I. V. Kolyadina, Y. V. Vishnevskaya, I. K. Vorotnikov, D. L. Stroyakovsky, N. A. Savelov, V. F. Semiglazov, А. G. Manikhas, А. V. Osheychik, T. B. Strelnikova, K. R. Zeynalova, L. G. Zhukova
Format: Artigo
Langue:Russo
Publié: Remedium Group LLC 2017-11-01
Collection:Медицинский совет
Sujets:
her2-positive breast cancer
neoadjuvant therapy
trastuzumab
Accès en ligne:https://www.med-sovet.pro/jour/article/view/2165
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires